Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
IPO Year:
Exchange: NASDAQ
Website: pumabiotechnology.com
Peers
Recent Analyst Ratings for Puma Biotechnology Inc
Date | Price Target | Rating | Analyst |
---|---|---|---|
9/28/2021 | $11.00 | Neutral → Buy | Citigroup |
9/28/2021 | Neutral → Buy | Citigroup | |
8/6/2021 | $13.00 → $6.00 | Sector Perform | RBC Capital |
8/6/2021 | $9.00 → $8.00 | Sell | Goldman Sachs |
Puma Biotechnology Inc Press Releases
Fastest customizable press release news feed in the world
Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that clinical data on neratinib will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2025. The AACR Annual Meeting will be held at the McCormick Place in Chicago, Illinois, from April 25–30, 2025. The title of the poster that will be presented is now available on the AACR Annual Meeting website at https://www.abstractsonline.com/pp8/#!/20273/presentation/10447. The full poster will be available on the Puma website concurrent with the live presentation. Poster Session: First-in-Human Phase I Clinical Trials 1 Abstract CT071: Title: Phase I trial of trastuzumab deruxtecan in co
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on March 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 3,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, March 1, 2025, a
Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 2:00 p.m. ET on Tuesday, March 11, at Barclays 27th Annual Global Healthcare Conference. The conference will be held at the Loews Miami Beach. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovat
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat
Puma Biotechnology to Present at TD Cowen's 45th Annual Health Care Conference
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder, will provide an overview of Puma at 11:10 a.m. ET on Wednesday, March 5, at the TD Cowen 45th Annual Health Care Conference. The conference will be held March 3–5, 2025 at the Boston Marriott Copley Place in Boston. A live webcast of the presentation will be available on the Puma Biotechnology website at https://www.pumabiotechnology.com. The presentation will be archived on the website and available for replay for 30 days. About Puma Biotechnology Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the deve
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approx
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 7,250 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, February 1
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on January 2, 2025, the Compensation Committee of Puma's Board of Directors approved the grant of inducement restricted stock unit awards covering 24,375 shares of Puma common stock to two new non-executive employees. The awards were granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit awards vest over a three-year period, with one-third of the shares underlying each award vesting on the first anniversary of the award's vesting commencement date, January 1,
Puma Biotechnology's NERLYNX® Included in NCCN Clinical Practice Guidelines for the Treatment of Cervical Cancer with a HER2 Mutation
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Cervical Cancer were updated to include an addition involving neratinib (NERLYNX®). The updated NCCN Practice Guidelines for Cervical Cancer include neratinib monotherapy for use as second-line or subsequent therapy for recurrent or metastatic disease as an option for patients with HER2-mutated tumors with a designation of Category 2A. The NCCN Guidelines Category of Preference is designated as "useful in certain circumstances" as a treatment option for patients with HER2-mutated tumors. This
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that on December 2, 2024, the Compensation Committee of Puma's Board of Directors approved the grant of an inducement restricted stock unit award covering 7,500 shares of Puma common stock to one new non-executive employee. The award was granted under Puma's 2017 Employment Inducement Incentive Award Plan, which was adopted on April 27, 2017 and provides for the granting of equity awards to new employees of Puma. The restricted stock unit award vests over a three-year period, with one-third of the shares underlying the award vesting on the first anniversary of the award's vesting commencement date, December 1,
Puma Biotechnology Inc Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
Puma Biotech. upgraded by Citigroup with a new price target
Citigroup upgraded Puma Biotech. from Neutral to Buy and set a new price target of $11.00
Puma Biotechnology upgraded by Citigroup
Citigroup upgraded Puma Biotechnology from Neutral to Buy
RBC Capital reiterated coverage on Puma Biotechnology with a new price target
RBC Capital reiterated coverage of Puma Biotechnology with a rating of Sector Perform and set a new price target of $6.00 from $13.00 previously
Goldman Sachs reiterated coverage on Puma Biotechnology with a new price target
Goldman Sachs reiterated coverage of Puma Biotechnology with a rating of Sell and set a new price target of $8.00 from $9.00 previously
Puma Biotechnology Inc Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Chief Financial Officer Nougues Maximo F was granted 61,456 shares, increasing direct ownership by 40% to 213,751 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Chief Commercial Officer Ludwig Jeffrey Jerome was granted 47,841 shares, increasing direct ownership by 44% to 156,792 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Officer Hunt Douglas M was granted 48,117 shares, increasing direct ownership by 39% to 172,711 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
President and CEO Auerbach Alan H was granted 198,399 shares, increasing direct ownership by 3% to 7,228,073 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Chief Financial Officer Nougues Maximo F sold $32,232 worth of shares (10,227 units at $3.15), decreasing direct ownership by 6% to 152,295 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Chief Commercial Officer Ludwig Jeffrey Jerome sold $29,743 worth of shares (9,437 units at $3.15), decreasing direct ownership by 8% to 108,951 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Officer Hunt Douglas M sold $27,209 worth of shares (8,633 units at $3.15), decreasing direct ownership by 6% to 124,594 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
President and CEO Auerbach Alan H sold $106,657 worth of shares (33,841 units at $3.15), decreasing direct ownership by 0.48% to 7,029,674 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Director Miller Michael Patrick sold $81,466 worth of shares (23,358 units at $3.49), decreasing direct ownership by 33% to 47,000 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Chief Financial Officer Nougues Maximo F sold $15,382 worth of shares (4,156 units at $3.70), decreasing direct ownership by 2% to 162,522 units (SEC Form 4)
4 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Issuer)
Puma Biotechnology Inc SEC Filings
SEC Form 10-K filed by Puma Biotechnology Inc
10-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Amendment: SEC Form SCHEDULE 13G/A filed by Puma Biotechnology Inc
SCHEDULE 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form 144 filed by Puma Biotechnology Inc
144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form 144 filed by Puma Biotechnology Inc
144 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form 10-Q filed by Puma Biotechnology Inc
10-Q - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Puma Biotechnology Inc filed SEC Form 8-K: Other Events
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
SEC Form S-8 filed by Puma Biotechnology Inc
S-8 - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Puma Biotechnology Inc filed SEC Form 8-K: Other Events
8-K - PUMA BIOTECHNOLOGY, INC. (0001401667) (Filer)
Puma Biotechnology Inc Leadership Updates
Live Leadership Updates
Puma Biotechnology to Join Russell 3000 Index
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, is set to join the broad-market Russell 3000® Index at the conclusion of Russell Investments' annual reconstitution of its comprehensive set of U.S. and global equity indexes on June 28 and effective after U.S. markets open on July 1, according to a preliminary list of additions posted on May 24. "We are very pleased to be included in the widely referenced Russell Indexes," said Alan H. Auerbach, Chief Executive Officer and President of Puma Biotechnology. "We believe that inclusion in the Russell 3000 will benefit our stockholders by increasing liquidity and providing exposure to a broader base of institutional investor
Summit Therapeutics Appoints Experienced Clinical Leader Dr. Alessandra Cesano to its Board of Directors
Menlo Park, California, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that Dr. Alessandra Cesano, MD, PhD, has been appointed to its Board of Directors, effective immediately. "Dr. Cesano compliments our Board of Directors with her decades of extensive experience in the global clinical development of oncology drugs," stated Robert W. Duggan, Chairman and Chief Executive Officer of Summit. "As we intend to expand our pipeline product portfolio into oncology, we are excited to add the wisdom and expertise that Alessandra can bring to our impressive leadership team. Her experience in developing both large and
Toragen, Inc. Announces the Appointment of Board of Directors and Senior Staff
Toragen is focused on uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV") Toragen, Inc., a San Diego-based biotechnology company focused on developing, repurposing and commercializing uniquely selective drugs targeting cancers caused by the human papillomavirus ("HPV"), announced today the appointment of Mr. Paul Engler, of Amarillo, Texas, to the Board of Directors of the Company. Additionally, Toragen announced the appointment of Cheryl Collett as CFO, effective June 20, 2022, and Dr. Richard Lumpkin as Director, Research & Development, effective July 1, 2022. Mr. Engler is the founder of Cactus Feeders. In 1960, he started the first cattle-feeding oper
ONK Therapeutics Appoints Hugh O’Dowd as Independent Chairman
GALWAY, Ireland & SAN DIEGO--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has appointed Hugh O’Dowd as Director and independent Non-executive Chairman of its Board of Directors. US-based Mr. O’Dowd brings significant experience and a background in the life sciences industry to the ONK Therapeutics’ Board in particular building organizations and commercialization of oncology therapeutics. His experience and strategic insights will be invaluable to ONK as it executes on its growth ambitions, progressing its novel, off-the-shelf, dual-targeted, natural killer (NK) cell therapy platform towards human clinical tri
Puma Biotechnology Inc Financials
Live finance-specific insights
Puma Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2024. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2024 compared to the fourth quarter and full year 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2024 was $54.4 million, compared to $53.2 million in the fourth quarter of 2023. Product revenue, net for the full year 2024 was $195.2 million, compared to $203.1 million in 2023. Based on accounting principles generally accepted in the United Stat
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PT/4:30 p.m. ET on Thursday, February 27, 2025, following the release of its fourth quarter and full year 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approx
Puma Biotechnology Reports Third Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2024. Unless otherwise stated, all comparisons are for the third quarter of 2024 compared to the third quarter of 2023. Product revenue, net consists entirely of sales revenue from NERLYNX®, Puma's first commercial product. Product revenue, net in the third quarter of 2024 was $56.1 million, compared to $51.6 million in the third quarter of 2023. Product revenue, net in the first nine months of 2024 was $140.8 million, compared to $149.9 million in the first nine months of 2023. Based on accounting principles generally accepted in the United States (GA
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, November 7, 2024, following the release of its third quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available shortly after complet
Puma Biotechnology Reports Second Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2024. Unless otherwise stated, all comparisons are for the second quarter 2024 compared to the second quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the second quarter of 2024 was $44.4 million, compared to product revenue, net of $51.6 million in the second quarter of 2023. Product revenue, net in the first six months of 2024 was $84.6 million, compared to $98.3 million in the first six months of 2023. Based on accounting principles generally accepted in th
Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hou
Puma Biotechnology Reports First Quarter Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2024. Unless otherwise stated, all comparisons are for the first quarter 2024 compared to the first quarter 2023. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net in the first quarter of 2024 was $40.3 million, compared to product revenue, net of $46.8 million in the first quarter of 2023. Based on accounting principles generally accepted in the United States (GAAP), Puma reported a net loss of $4.8 million, or $0.10 per basic and diluted share, for the first quarter of 2024,
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, May 2, 2024, following the release of its first quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-201-689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available approximately one hour af
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2023. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2023 compared to the fourth quarter and full year 2022. Product revenue, net consists entirely of revenue from sales of NERLYNX®, Puma's first commercial product. Product revenue, net for the fourth quarter of 2023 was $53.2 million, compared to $53.7 million in the fourth quarter of 2022. Product revenue, net for the full year 2023 was $203.1 million, compared to $200.0 million in 2022. Based on accounting principles generally accepted in the United Stat
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, February 29, 2024, following the release of its fourth quarter and full year 2023 financial results. The call may be accessed by dialing (877) 709-8150 (domestic) or (201) 689-8354 (international). Please dial in at least 10 minutes in advance and inform the operator that you would like to join the "Puma Biotechnology Conference Call." A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at https://www.pumabiotechnology.com. A replay of the call will be available appr
Puma Biotechnology Inc Large Ownership Changes
This live feed shows all institutional transactions in real time.
SEC Form SC 13G filed by Puma Biotechnology Inc
SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G filed by Puma Biotechnology Inc
SC 13G - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)
SEC Form SC 13G/A filed by Puma Biotechnology Inc (Amendment)
SC 13G/A - PUMA BIOTECHNOLOGY, INC. (0001401667) (Subject)